Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial
Resource Type
Article
Authors
Madhi, Shabir A ; Moodley, Dhayendre ; Hanley, Sherika ; Archary, Moherndran ; Hoosain, Zaheer ; Lalloo, Umesh ; Louw, Cheryl ; Fairlie, Lee ; Fouche, Leon Frederik ; Masilela, Mduduzi S L ; Singh, Nishanta ; Grobbelaar, Coert ; Ahmed, Khatija ; Benadé, Gabriella ; Bhikha, Sutika ; Bhorat, As'ad Ebrahim ; Bhorat, Qasim ; Joseph, Natasha ; Dheda, Keertan ; Esmail, Aliasgar ; Foulkes, Sharne ; Goga, Ameena ; Oommen Jose, Aylin ; Kruger, Gertruida ; Kalonji, Dishiki J ; Lalloo, Natasha ; Lombaard, Johan J ; Lombard Koen, Anthonet ; Kany Luabeya, Angelique ; Mngqibisa, Rosie ; Petrick, Friedrich G ; Pitsi, Annah ; Tameris, Michele ; Thombrayil, Asha ; Vollgraaff, Pieter-Louis ; Cloney-Clark, Shane ; Zhu, Mingzhu ; Bennett, Chijioke ; Albert, Gary ; Faust, Emmanuel ; Plested, Joyce S ; Fries, Lou ; Robertson, Andreana ; Neal, Susan ; Cho, Iksung ; Glenn, Greg M ; Shinde, Vivek
Source
In The Lancet HIV May 2022 9(5):e309-e322
Subject
Primary Research Articles
Language
ISSN
2352-3018